

Third Quarter Business Results for Fiscal 2020

Feburary 8, 2021(Monday) Director,

Managing Executive Officer and CFO

Muneki Handa

Third Quarter Business Results for FY 2020

(Million yen)

					(i iiiioii yeiiy				
		FY 2020	FY 2019	Y	σΥ				
		3Q actual	3Q actual	Amount	Change				
	Net sales	99,482	95,185	+4,296	+4.5%				
	Operating profit (Operating profit margin)	17,560 (17.7%)	16,151 (17.0%)	+1,409	+8.7%				
	Ordinary profit	18,136	16,675	+1,461	+8.8%				
	Profit attributable to owners of parent	13,356	11,690	+1,665	+14.2%				
		0% 20%	40%	60%	80% 100%				
Ratio to total sales		Pres	cription Kampo Pro 91.6% 0.4%	oducts 3.3%	4.7%				
	O.470 - 5.5% - 4.7% - 4.7% - 4.7% - 4.7% - 5.5% - 5.5% - 5.5% - 4.7% - 5.5% - 5.5% - 5.5% - 5.5% - 5.5% - 5.5%								

Key Points in Performance



Consequently, net sales and profits were up in comparison with the same period a year earlier.

Net sales	99,482	million yen	ΥοΥ	+4.5%
		-		

- Net sales rose 4.5% year-on-year owing to the consolidation of a subsidiary in China.
- Sales of the 129 prescription Kampo products climbed 0.5% year-on-year.
- Sales of healthcare products including OTC Kampo medicines increased 17.4% year-on-year.

Operating profit	17,560 million yen	YOY	+8.7%
Operating profit margin	17.7%	YOY	+0.7pt

- The cost-to-sales ratio was 41.5%, a rise of 0.4pt year-on-year. Although crude drug-related costs were absorbed by a rise in NHI drug price revisions, the increase in the cost-to-sales ratio reflects impact from external sales in China.
- The SG&A ratio totaled 40.8%, a decline of 1.1pt year-on-year, mainly reflecting unused expenses in tandem with restricted activities due to impact from COVID-19.

Ordinary profit	18,136	million yen	YOY	+8.8%
Profit attributable to owners of parent	13,356	million yen	YOY	+14.2%

Sales of Drug-fostering Program Formulations/Growing Formulations



(Million ven)

						(141	mon yen)
	Net sales Ranking	Product	No./formulation name	FY 2019 3Q	FY 2020 3Q	Yo	Y
Dru	1	100	Daikenchuto	8,023	8,005	(18)	(0.2)%
Drug-fostering program formulations	2	54	Yokukansan	6,028	6,068	40	0.7%
ering nulati	4	43	Rikkunshito	5,726	5,806	80	1.4%
progi ons	8	107	Goshajinkigan	2,813	2,786	(27)	(1.0)%
am.	24 14 Hangeshashinto		1,094	1,093	(1)	(0.1)%	
Тс	Total sales for drug-fostering program formulations			23,685	23,759	73	0.3%
Gro	3	41	Hochuekkito	5,589	5,986	396	7.1%
owing	5	68	Shakuyakukanzoto	4,112	3,956	(156)	(3.8)%
ı form	9	29	Bakumondoto	3,682	2,714	(967)	(26.3)%
Growing formulations	7	24	Kamishoyosan	3,621	3,765	143	4.0%
suc	6	17	Goreisan	3,522	3,850	328	9.3%
	Total s	ales for gro	wing formulations	20,528	20,273	(255)	(1.2)%
1			ulations other than drug- I growing formulations	46,507	47,108	600	1.3%
	Total sales fo	or 129 prese	cription Kampo products	90,722	91,141	419	0.5%



Comparison with the prescription pharmaceutical market

Prescription	(2,2)	(Drug price basis)		
pharmaceutical market	(3.2)%	Gap with market: 4.8pt		
Tsumura	+ 1.6% (YoY)	Copyright © 2021 IQVIA. Estimated based on IQVIA JPM Apr.2019-Dec.2020. Reprinted with permission		

Sales trends by sales channel

(Actual sale/selling price basis)

General clinics +2 (Ratio to total sales: 77%) (


Hospitals (2.6)% (YoY)

+**2.3%** (YoY) Although prescriptions for cold-related products declined, prescription growth was positive mainly for the treatment of skin diseases and mental disorders

Substantial impact due to restricted activities Decline mainly in the number of outpatients and surgeries performed

Positive/Negative COVID-19 Impact





Factors Triggering Changes in Operating Profit (YoY)

|--|

				(Million yen)		(Million yen)		
	+2,528	(410)			Changes in sales cos (410) Breakdo			
			(709)		Unit selling price/ composition	(497)		
				17,560	Crude drug cost/ Raw material cost	+1,492		
					Processing cost	+198		
					External sales in China	(1,603)		
16,151					Changes in SG&A e (709)Breakd	and a second		
					Sales-related expenses	(495)		
					R&D expenses	(184)		
3Q FY 2019	Profit impact	Profit impact	Profit impact	3Q FY 2020	Travel/transportation expenses	+677		
Operating profit	due to changes in sales	due to changes from changes		due to changes in sales cost from changes in SG&A expenses		Operating profit	Other	(707)


Financial Condition/Cash Flow Position

			(Million yen	ı)						
	FY 2019 (March 2020)	FY 2020 3Q	Change				(H	lundre	ed millior	ı yen)
Total assets	311,042	312,895	1,852		+126	(40)				
Current assets	194,288	199,310	5,021		F120	(49)				
Non-current assets	116,753	113,584	(3,168)				(97)			
Total liabilities	97,993	85,356	(12,636)							
Current liabilities	48,476	44,995	(3,481)						+35 5	590
Non-current liabilities	49,516	40,361	(9,155)	576				(1)	T 35 S	550
Total net assets	213,048	227,538	14,489							
Equity ratio	66.0%	68.1	2.1pt							
				<u></u> с		Ц	⊐ ⊄	브	ק ב	
	FY 2019 (March 2020)	FY 2020 3Q	Change	Casn and casn equivalents at beginning of period	Operating activities	Investing activities	translations Financing activities	Impact of exchange rate	Period New consolidation	Cash and cash
Inventories	73,310	75,397	2,087	g of	ng a	g ac	ig ac	ofe	nsoli	d cas
Merchandise and finished goods	10,338	11,973	1,634	in equ	ctivit	tiviti	ctiviti	kchai	datio	+ 57
Work in process	12,418	13,419	1,000	iies uival		es	es	nge	n c	
Raw materials and supplies	50,553	50,005	(548)	ents				rate		
				at	-					8

8

TSUMURA

Roadmap to Realizing Long-Term Vision



Strategic challenges

- 1. Sustainably expanding the Kampo market and establishing a presence
- 2. Investing in growth and building business foundations in China
- 3. Improving productivity using new technologies —AI, robotization, RPA

- 4. Fostering a corporate culture through philosophybased management and developing diverse human resources
- 5. Promoting SDGs through the Kampo Value Chain

Three Important Domains in the Domestic Market **P**TSUMURA


- Positioned geriatric health; cancer (supportive care) and women's health as the three important domains and aim to concentrate our activities in these domains
- We plan to deploy a sales approach in the drug-fostering program formulations, growing formulations and three important domains

Geriatric he	ealth domain	Cancer domain (supportive care)	Women's health domain
Psychiatric and neurological disorders	Digestive system diseases	Mitigation of side effects, etc.	Diseases specific to women
Yokukansan + related formulations	 Rikkunshito Daikenchuto 	D RikkunshitoD Hangeshashinto	G Kamishoyosan + related formulations
Respiratory diseases	G Hochuekkito	D Goshajinkigan	
G Bakumondoto + related formulations	+ related formulations	+ related formulations	Other diseases and symptoms Daikenchuto
Peripheral symptoms G Goreisan + rela	for circulatory disorders		G Goreisan + related formulations





Visitations + e-promotion




*2 CME digital : Lifetime education on Kampo medicine for medical practitioners, including physicians (Continuing Medical Education)

e-promotion



= New form of information provision activities



Tokishigyakukagoshuyu

shokyoto



[Target] Physicians that write nine or less Kampo prescriptions and physicians that do not write Kampo prescriptions

1Q-3Q actual ■No. of times held: **6**; ■Total number of viewers: **133,727**

3Q themes	Prescriptio	n Lecturer	Date held No. of viewers
Are there opportunities for the use of Kampo in treating heart failure in seniors? -7 symptoms and 11 formulations to remember-	Goreisan, Mashinir Hochuekkito, Daiker Goshajinkigan, Nin etc.	chuto, Dr. Junichiro Dokura	
Cold sensitivity and qi, blood and fluid in women	Tokishigyakukagosh kyoto Unkeito	uyusho Dr. Aya Maruyama Kasumigaseki Building Cli	nic 25,922 viewers
			(YoY)
Prescriptio	n	Prescriptio	on
Goreisan	+9.3%	Daikenchuto	(0.2)%
Mashiningan	+8.7%	Unkeito	(0.4)%
Hochuekkito	+7.1%	Goshajinkigan (1.	

+4.0%

Ninjinto


(4.0)%

Area Plans and Area Online Lectures




Area plans Provide detailed information taking into consideration regional traits and facility features "Introductory seminar on Kampo medicine" for physicians wanting to learn about Kampo

Examples of themes: Dizziness, headaches, stress, sleep disorders, introduction to Kampo, etc.



Examples of lectures held: As a result of holding lectures on Kampo at university hospitals that have no track record in administering Kampo, there was a ripple effect to various areas, including new use of Kampo at related hospitals.

Medium-term Management Plan and Vision for the **China Business**



Revisions to FY 2020 Earnings Forecast

(Million yen)

	Initial plan Revised		Comparison w	ith initial plan	YoY		
		plan	Amount	Change	Amount	Change	
Net sales	132,000	130,500	(1,500)	(1.1)%	+7,251	+5.9%	
Operating profit	17,000	19,300	+2,300	+13.5%	+423	+2.2%	
Ordinary profit	17,900	20,200	+2,300	+12.8%	+550	+2.8%	
Profit attributable to owners of parent	13,000	15,000	+2,000	+15.4%	+1,234	+9.0%	


	Initial plan	Revised plan	FY 2019
Operating profit margin	12.9%	14.8%	15.3%
Dividend (per share)	¥64 (forecast)	¥64 (forecast)	¥64
EPS	¥169.92	¥196.06	¥179.96
ROE	6.2%	7.1%	6.8%

(Note) The above forecasts were prepared based on the information available as of the date of publication of this presentation. Accordingly, the impact of risks that cannot be predicted at this time, including the impact on socio-economic activities from the further spread of COVID-19, have not been factored in. Actual earnings performance may differ from the forecasts stated herein owing to various factors going forward. We will disclose trends and conditions in a timely and proper manner should there be any changes in the circumstances surrounding our company.



Policy

We aim to improve our corporate value by continually expanding our Kampo business and through growth investments in the China business, and by building foundations. Accordingly, we plan to implement stable dividends, taking into account factors such as medium/long-term profit levels and cash flow conditions.



Note: The FY 2020 year-end dividend and payout ratio (forecast) are an estimate based on the assumption that the dividend resolution is approved at the 85th Ordinary General Meeting of Shareholders.




Corporate Communications Dept. Investor Relations Group investor_madoguchi@mail.tsumura.co.jp

Cautionary items regarding forecasts

- The materials and information provided in this presentation contain so-called forward-looking statements. Readers should be aware that the realization of these statements can be affected by a variety of risks and uncertainties and that actual results could differ significantly.
- Changes in Japan or other foreign countries related to healthcare insurance systems or regulations set by medical treatment authorities on drug prices or other aspects of healthcare or in interest and foreign exchange rates could negatively impact the Company's performance or financial position.
- In the unlikely event that sales of the Company's core products currently on the market be halted or should sales substantially decline due to a defect, unforeseen side effect or some other factor, there could be a major impact on the Company's performance or financial position.

appendix

Scale of the Traditional Chinese Medicine Market



Source: National Bureau of Statistics of China, Ministry of Industry and Information Technology (MIIT)

Terminology	Definition	Corresponding terminology for Kampo medicine (Meanings are not always the same)	
Chinese medicine	Medicines used in traditional Chinese medicine (traditional Chinese medical products, drug pieces, etc.)	Kampo, crude drug pieces, crude drugs	
Drug pieces	Same meaning as crude drug pieces, Use as a decoction	Crude drug pieces	
Traditional Chinese medical products	Drugs in the form of granules, pills or other shapes based on the theories of traditional Chinese medicine	Kampo extract formulations, crude drug production	
(Manufacturing of classical prescription Chinese medicine complex formulations)	(Drugs in the form of granules, pills or other shapes based on old traditional Chinese medical books)	(Kampo extract formulations)	


*Source: Production statistics, including for Kampo formulations, Japan Kampo Medicine Manufacturers Association

China Business: Diagram of Capital Ties



Structure of the China business and capital ties: Ownership ratios

as of the end of December 2020



Roadmap for the Chinese Business Vision (image)



		2019	2020	2021	2022 ~	2027
Shenzhen Tsumura	Cri	Manufactur	ring and s	ales of rav	w material crude	e drugs and drug pieces (FY 2018 onward)
Ping An Tsumura Pharmaceutical Co., Ltd.	Crude drug platform	[Manu	facturing	and sales of raw	v material crude drugs and drug pieces
Pingcun Zhongying	g platfc		Manufacturing of food products, including raw material crude drugs and Yakushokudogen products			
Pingcun Medical	rm		Sales of food products, including Yakushokudogen products			
Tsumura Shengshi	Formulation	Start up operat	ions at Tiar	njin Plant ir		Acturing of Kampo powdered extract (for Tsumura) Manufacturing of classical prescription Chinese medicine complex formulations
Shanghai Tsumura		Manufacturing of Kampo powdered extract (for Tsumura)				
				N		Manufacturing of classical prescription Chinese medicine complex formulations
Traditional Chinese medical products Company	platform		M&A	¥	Existing produ	M&A Icts at M&A partners (traditional Chinese medical
					proc	ducts) and acquisition of sales channels Manufacturing of classical prescription Chinese medicine complex formulations
Ping An Tsum Traditional Chin Medicine Resea Center (working n	ese rch		h Traditional arch Center (\			Operation

*Change name to Traditional Chinese Medicine Research Center (working name) 22